BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26972187)

  • 21. [New developments in Sézary syndrome].
    Caudron A; Marie-Cardine A; Bensussan A; Bagot M
    Ann Dermatol Venereol; 2012 Jan; 139(1):31-40. PubMed ID: 22225740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma.
    LeBlanc RE; Lefterova MI; Suarez CJ; Tavallaee M; Kim YH; Schrijver I; Kim J; Gratzinger D
    Hum Pathol; 2015 Sep; 46(9):1382-9. PubMed ID: 26193796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
    Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
    Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription.
    Wang Y; Su M; Zhou LL; Tu P; Zhang X; Jiang X; Zhou Y
    Blood; 2011 Apr; 117(14):3826-35. PubMed ID: 21270445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sézary syndrome.
    Roelens M; de Masson A; Andrillon A; Ram-Wolff C; Biard L; Boisson M; Mourah S; Battistella M; Toubert A; Bagot M; Moins-Teisserenc H
    Br J Dermatol; 2022 Jun; 186(6):1010-1025. PubMed ID: 35041763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression pattern of chemokine receptors and chemokine release in inflammatory erythroderma and Sézary syndrome.
    Fierro MT; Comessatti A; Quaglino P; Ortoncelli M; Osella Abate S; Ponti R; Novelli M; Bernengo MG
    Dermatology; 2006; 213(4):284-92. PubMed ID: 17135733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.
    van der Fits L; van Kester MS; Qin Y; Out-Luiting JJ; Smit F; Zoutman WH; Willemze R; Tensen CP; Vermeer MH
    J Invest Dermatol; 2011 Mar; 131(3):762-8. PubMed ID: 21085192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
    Edelson RL
    Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sézary syndrome without erythroderma.
    Henn A; Michel L; Fite C; Deschamps L; Ortonne N; Ingen-Housz-Oro S; Marinho E; Beylot-Barry M; Bagot M; Laroche L; Crickx B; Maubec E
    J Am Acad Dermatol; 2015 Jun; 72(6):1003-9.e1. PubMed ID: 25981000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TOX expression in different subtypes of cutaneous lymphoma.
    Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases.
    Klemke CD; Booken N; Weiss C; Nicolay JP; Goerdt S; Felcht M; Géraud C; Kempf W; Assaf C; Ortonne N; Battistella M; Bagot M; Knobler R; Quaglino P; Arheiliger B; Santucci M; Jansen P; Vermeer MH; Willemze R
    Br J Dermatol; 2015 Jul; 173(1):93-105. PubMed ID: 25864856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The Sézary syndrome].
    Ferreira F; Correia TM; Callabro L; Andrade J
    Acta Med Port; 1998 Dec; 11(12):1135-9. PubMed ID: 10192992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome.
    Sokolowska-Wojdylo M; Wenzel J; Gaffal E; Steitz J; Roszkiewicz J; Bieber T; Tüting T
    Clin Exp Dermatol; 2005 Nov; 30(6):702-6. PubMed ID: 16197392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From single-cell signature to prognostic factors: the case of Sézary syndrome.
    Scala E; Narducci MG; Russo G
    Expert Rev Clin Immunol; 2012 Nov; 8(8):699-701. PubMed ID: 23167680
    [No Abstract]   [Full Text] [Related]  

  • 36. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
    Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
    J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Xenograft and cell culture models of Sézary syndrome reveal cell of origin diversity and subclonal heterogeneity.
    Poglio S; Prochazkova-Carlotti M; Cherrier F; Gros A; Laharanne E; Pham-Ledard A; Beylot-Barry M; Merlio JP
    Leukemia; 2021 Jun; 35(6):1696-1709. PubMed ID: 33106625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Gene Mutations and Fusion Genes in Patients with Sézary Syndrome.
    Prasad A; Rabionet R; Espinet B; Zapata L; Puiggros A; Melero C; Puig A; Sarria-Trujillo Y; Ossowski S; Garcia-Muret MP; Estrach T; Servitje O; Lopez-Lerma I; Gallardo F; Pujol RM; Estivill X
    J Invest Dermatol; 2016 Jul; 136(7):1490-1499. PubMed ID: 27039262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Mutations Involving NF-κB and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sézary Syndrome.
    Kim EJ; Lewis DJ; Duvic M
    J Invest Dermatol; 2017 Sep; 137(9):1831-1833. PubMed ID: 28843295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.